United States: Capitol Hill Healthcare Update - April 2017

GOP Struggles To Revive Health Bill

House Republicans of all ideological stripes say they are committed to rekindling interest in the American Health Care Act (AHCA), but while the interest is real, so too are the policy and political divisions that thwarted passage of the bill last month.

When House Speaker Paul Ryan and other GOP leaders said intra-party discussions would continue with the hopes of reaching consensus and a possible vote on the AHCA, it wasn't happy talk. Rank-and-file Republicans say keeping the Affordable Care Act (ACA) in place presents at least as many political problems as the party's effort to repeal it. For example, failing to repeal the $1 trillion in ACA taxes significantly complicates the GOP's goal of enacting sweeping tax reform later this year.

The House won't reconsider the AHCA legislation this week before lawmakers adjourn for a two-week recess. Even after Congress reconvenes April 25, immediate budget deadlines that threaten a potential government shutdown will likely be lawmakers' top priority.

If there's a window to reconsider the AHCA, it's likely in May. But it's a narrow window.

The Republicans' process to repeal the ACA includes using a procedural tool known as budget reconciliation, which shields the bill from a Senate filibuster. Without that shield, Republicans would be forced to persuade at least eight Senate Democrats to vote with them – a political non-starter.

But the reconciliation legislation that the GOP is using to partially repeal and replace the ACA has a half-life. It will expire when Congress begins drafting the fiscal 2018 budget blueprint, which will likely be sometime in May. So if Republicans want to resurrect the AHCA and avoid the need for bipartisan votes in the Senate, they will have to vote on the bill within the next several weeks.

Still, despite the positive statements by Ryan and other Republicans, the intra-party squabbles that derailed the bill remain – and show no signs of abating. President Trump's recent Twitter attacks against the conservative leaders of the Freedom Caucus did little other than harden their opposition. Trump has talked about trying to create a coalition of moderate Democrats and Republicans to pass an ACA repeal bill. But the policy concessions needed to attract Democrats would likely repel just as many Republicans.

Ten days after Republicans' remarkable decision to cancel the House vote on the AHCA, their healthcare legislation isn't dead, but it is on life-support.

FDA Would Mostly Grind To A Halt Under Shutdown

The last time the government closed because of budget brinkmanship in Washington, the FDA and many other federal health agencies were virtually shuttered and thousands of employees were furloughed. Congress is scheduled to be in session for only eight days this month before facing an April 28 deadline to approve new spending or risk a government shutdown. While GOP leaders on Capitol Hill are adamant that they won't let the government close, some Republican lawmakers are warning that the intra-party feuding over funding for the Pentagon, Planned Parenthood and the Affordable Care Act makes the risk of a shutdown real.

During the last shutdown four years ago, nearly half of the FDA's 14,000 employees were furloughed. Although critical functions like high-risk recalls and the monitoring of adverse-event reporting continued, most FDA functions were shuttered, including inspections, monitoring and enforcement. FDA programs funded by user fees weren't totally immune during the last shutdown. Advisory committee meetings were postponed, and some drug and medical device manufacturers saw delays in approvals, although reviews continued. But the FDA didn't accept any new drug or device applications during the 2013 shutdown.

The Trump administration has latitude to determine which agency and personnel are deemed critical and will stay operational even if the government is closed. But industry stakeholders with planned advisory committees or scheduled agency interactions could face disruption and delays during a shutdown.

Senate Panel Considered Gottlieb This Week

The Senate Health, Education, Labor and Pensions (HELP) Committee considered Dr. Scott Gottlieb's nomination to be the FDA commissioner on Wednesday.

The committee's chairman, Sen. Lamar Alexander (R-Tenn.), pronounced Gottlieb "well-qualified" during a one-on-one meeting last month. Gottlieb has held a series of positions within FDA, including deputy commissioner, and has served at the Centers for Medicare & Medicare Services (CMS).

But the top Democrat on the panel, Sen. Patty Murray (D-Wash.), said she is "deeply concerned" that Gottlieb is too close to the industries the FDA regulates. Gottlieb served as a consultant and board member to several pharmaceutical manufacturers, and he also announced he would recuse himself from agency considerations affecting 20 companies.

Alexander announced that a full Senate vote on Dr. Gottlieb's nomination will likely occur later this month after the Senate returns from a two-week recess.

Dems' Bills Take Aim At Drug Manufacturers

Nearly two dozen House and Senate Democrats introduced sweeping legislation last week that directly confronts the pharmaceutical industry in the battle over prescription drug costs. The Democrat-only bills, introduced separately in the House and Senate, include virtually every adverse provision ever proposed against the drug industry, including:

  • Allowing Medicare to negotiate drug prices
  • Extending Medicaid rebates to Medicare beneficiaries
  • Importing prescription drugs from other countries
  • Lowering exclusivity for biologics from 12 years to seven years
  • Applying an excise tax on companies that raise drug prices more than medical inflation
  • Shrinking exclusivities so the FDA can accept generic applications after three years instead of five years
  • Preventing manufacturers from deducting the cost of consumer advertising
  • Requiring companies to disclose research, manufacturing and marketing costs

Led by Sen. Al Franken (D-Minn.), the far-reaching legislation attracted support from other senators, including Bernie Sanders (I-Vt.), Elizabeth Warren (D-Mass.), Kirsten Gillibrand (D-N.Y.), Dick Durbin (D-Ill.), Richard Blumenthal (D-Conn.) and Cory Booker (D-N.J.). The Senate bill – a companion bill was introduced in the House – also was endorsed by 15 public-sector unions and consumer groups.

It's unlikely the House and Senate bills will gain traction in the Republican-controlled Congress, where GOP lawmakers have long opposed nearly every provision in the legislation. Still, the Democrats hope to piggy-back on mounting attention over prescription drug prices and even President Trump's statements against the industry. The White House hasn't announced a specific plan to reduce drug prices or endorsed any legislative efforts, including Franken's.

Senate Bill Seeks To Improve Local Coverage Determination Process

Bipartisan legislation introduced in the Senate aims to provide transparency and predictability to the local coverage determination process used by Medicare Administrative Contractors (MACs). Industry and congressional critics have long complained that the contractors' use of the process lacks transparency and meaningful stakeholder input. That process also is not defined in statute, leaving the contractors with latitude to set their own guidelines in 10 regions across the country. Introduced by Sens. Johnny Isakson (R-Ga.), Thomas Carper (D-Del.), Debbie Stabenow (D-Maine) and John Boozman (R-Ark.), the bill would require open and public MAC meetings, disclosure by MACs of the rationale for local coverage decisions, and providing the industry with a meaningful reconsideration process for decisions. Similar legislation was introduced in the last Congress, but it didn't pass.

Senate Panel Holds User Fee Hearing

The Senate HELP Committee on Tuesday held its second hearing on FDA user fees, featuring witnesses representing medical device, biotechnology and generic drug manufacturers. Witnesses included Kay Holcombe of BIO, David Gaugh of Association for Accessible Medicines (formerly GPhA), Scott Whitaker of AdvaMed, and Cynthia Bens of the Alliance for Aging Research. The FDA's current user fee agreements expire September 30, and Congress is reviewing the several industry deals with the agency.

Key Appropriator Nixes Trump's NIH Cuts

The chairman of the House appropriations panel that funds federal health programs and agencies rejected President Trump's proposed spending cuts for the National Institutes of Health (NIH). Rep. Tom Cole (R-Okla.) reiterated his support for NIH funding during a subcommittee hearing last week with HHS Secretary Tom Price, who faced bipartisan criticism over the president's proposed cuts. The White House wants to reduce NIH spending by $5.8 billion, a cut of about 20 percent. Price said Trump wants to reduce NIH's spending only on administration, not on research and grant funding. NIH has enjoyed long-standing bipartisan support in Congress, and lawmakers in December boosted NIH funding by $4.8 billion.

Healthcare Cybersecurity Focus Of Hearing

The House Energy and Commerce Subcommittee on Oversight and Investigations held a hearing Tuesday on how government and industry can better partner to enhance healthcare cybersecurity. Witnesses included Denise Anderson of the National Health Information Sharing and Analysis Center, Michael McNeil of Royal Philips, and Terry Rice, the chief information security officer at Merck. The subcommittee's chairman, Rep. Tim Murphy (R-Pa.), said efforts to bolster cybersecurity in the healthcare sector have been "sporadic and largely ineffective."

The hearing addressed ways to strengthen the National Health Information Sharing and Analysis Center and the Healthcare and Public Health Sector Coordinating Council. The lawmakers also reviewed HHS's role as a so-called Sector-Specific Agency, which charges the department with providing support and guidance to industry stakeholders and implementing government-wide cybersecurity initiatives and strategies.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.